4588 Stock Overview Engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Oncolys BioPharma Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Oncolys BioPharma Historical stock prices Current Share Price JP¥506.00 52 Week High JP¥918.00 52 Week Low JP¥420.00 Beta 0.61 1 Month Change -28.02% 3 Month Change -13.06% 1 Year Change -0.98% 3 Year Change -21.06% 5 Year Change -74.21% Change since IPO -85.67%
Recent News & Updates
Is Oncolys BioPharma (TSE:4588) Using Debt Sensibly? Dec 20
Oncolys BioPharma Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025 Dec 03
New major risk - Financial position Nov 14
Oncolys BioPharma Inc. to Report Q3, 2024 Results on Nov 08, 2024 Aug 28
Second quarter 2024 earnings released: JP¥18.72 loss per share (vs JP¥31.47 loss in 2Q 2023) Aug 14
Oncolys BioPharma Inc. Announces Complete Enrollment of Phase I Clinical Trial for Telomelysin (OBP-301) - Chemoradiation Combination Therapy Aug 06 See more updates
Is Oncolys BioPharma (TSE:4588) Using Debt Sensibly? Dec 20
Oncolys BioPharma Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025 Dec 03
New major risk - Financial position Nov 14
Oncolys BioPharma Inc. to Report Q3, 2024 Results on Nov 08, 2024 Aug 28
Second quarter 2024 earnings released: JP¥18.72 loss per share (vs JP¥31.47 loss in 2Q 2023) Aug 14
Oncolys BioPharma Inc. Announces Complete Enrollment of Phase I Clinical Trial for Telomelysin (OBP-301) - Chemoradiation Combination Therapy Aug 06
Is Oncolys BioPharma (TSE:4588) A Risky Investment? Jun 17
New major risk - Financial position Jun 16
New major risk - Financial position May 29
Health Check: How Prudently Does Oncolys BioPharma (TSE:4588) Use Debt? Feb 29
New major risk - Financial position Feb 11
Full year 2023 earnings released: JP¥107 loss per share (vs JP¥66.31 loss in FY 2022) Feb 10
Oncolys BioPharma Inc., Annual General Meeting, Mar 28, 2024 Feb 09
Oncolys Biopharma Inc. Announces the Investigator-Initiated Phase 2 Clinical Trial Agreement with Weill Cornell Medicine Dec 20 Oncolys BioPharma Inc. to Report Q1, 2024 Results on May 10, 2024
New major risk - Financial position Nov 13
Third quarter 2023 earnings released: JP¥23.01 loss per share (vs JP¥15.28 loss in 3Q 2022) Nov 13
Oncolys Biopharma Inc. Provides Update on Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Gastroesophageal (GEA) Adenocarcinoma Nov 07
Oncolys Biopharma Announces Enrollment of First Expansion Cohort Patient in Phase I Clinical Trial for Telomelysin (OBP-301)-Chemoradiation Combination Therapy Nov 02
Oncolys BioPharma Inc. Announces Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy Oct 17
New minor risk - Shareholder dilution Sep 22
Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin™? in Combination Therapy Aug 11
Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin™? in Combination Therapy Aug 10
New minor risk - Revenue size Aug 06
Second quarter 2023 earnings released: JP¥31.47 loss per share (vs JP¥13.94 loss in 2Q 2022) Aug 05 Oncolys Biopharma Inc. Announces Enrollment of First Patient in Phase Iia Study for Obp-601 in Patients with Aicardi-Goutieres Syndrome
First quarter 2023 earnings released: JP¥18.69 loss per share (vs JP¥18.98 loss in 1Q 2022) May 13
Full year 2022 earnings released: JP¥66.31 loss per share (vs JP¥95.50 loss in FY 2021) Feb 14
Oncolys BioPharma Inc., Annual General Meeting, Mar 29, 2023 Feb 10 Oncolys BioPharma Inc. to Report Q3, 2023 Results on Nov 10, 2023
No independent directors Nov 16
Oncolys Biopharma Inc. Provides Financial Forecast for the Fiscal Year Ending December 31, 2022 Nov 05
Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with Progressive Supranuclear Pals Aug 18
Second quarter 2022 earnings released: JP¥13.94 loss per share (vs JP¥17.34 loss in 2Q 2021) Aug 08
Oncolys BioPharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022 Aug 06
Oncolys BioPharma Inc. SHS to Be Deleted from OTC Equity Jul 30
Oncolys BioPharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022 May 15
First quarter 2022 earnings released: JP¥18.98 loss per share (vs JP¥22.36 loss in 1Q 2021) May 14
No independent directors Apr 27 Oncolys BioPharma Inc. to Report Q3, 2022 Results on Nov 04, 2022
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 14 Oncolys Biopharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022
Oncolys BioPharma Inc. Announces Enrollment of First Patient in Phase IIa study for OBP-601 Jan 22
Oncolys BioPharma Inc. Announces First Patient Dosed in NRG Oncology Phase I Clinical Trial for Telomelysin in Chemoradiation Combination Therapy for Esophageal Cancer Patients Dec 08
Second quarter 2021 earnings released: JP¥17.34 loss per share (vs JP¥26.48 loss in 2Q 2020) Aug 09
Oncolys Biopharma Inc. Announces of the Effect of OBP-2011 Against SARS and MERS Jun 30
Oncolys Biopharma Inc. Provides Earnings Guidance for the Year Ending December 31, 2021 May 08
Oncolys BioPharma Inc. Announces That the First Patient Has Been Enrolled in the Investigator- Initiated Phase II Clinical Trial for Telomelysin (OBP-301) -Pembrolizumab and Stereotactic Radiation Combination Therapy for Head and Neck Cancer Patients May 06
Full year 2020 earnings released: JP¥146 loss per share (vs JP¥65.56 loss in FY 2019) Feb 17
New 90-day low: JP¥1,385 Feb 12
Oncolys BioPharma Inc. announced that it has received ¥42.9024 million in funding from SMBC Nikko Securities Inc., Investment Arm Jan 05
New 90-day low: JP¥1,525 Dec 11
Oncolys BioPharma Enters into Business Alliance Agreement with Asahi Intecc Co., Ltd Dec 11
Oncolys BioPharma Inc. Announces Receipt of Upfront Payment in Accordance with License Agreement for OBP-601 (Censavudine) Dec 04 Oncolys BioPharma Inc. to Report First Half, 2021 Results on Aug 06, 2021 Shareholder Returns 4588 JP Biotechs JP Market 7D -22.9% -1.7% -1.5% 1Y -1.0% 18.5% 13.7%
See full shareholder returns
Return vs Industry: 4588 underperformed the JP Biotechs industry which returned 18.5% over the past year.
Return vs Market: 4588 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility Is 4588's price volatile compared to industry and market? 4588 volatility 4588 Average Weekly Movement 11.2% Biotechs Industry Average Movement 6.9% Market Average Movement 3.6% 10% most volatile stocks in JP Market 7.3% 10% least volatile stocks in JP Market 1.9%
Stable Share Price: 4588's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4588's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company’s product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use.
Show more Oncolys BioPharma Inc. Fundamentals Summary How do Oncolys BioPharma's earnings and revenue compare to its market cap? 4588 fundamental statistics Market cap JP¥12.56b Earnings (TTM ) -JP¥1.91b Revenue (TTM ) JP¥31.38m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4588 income statement (TTM ) Revenue JP¥31.38m Cost of Revenue JP¥0 Gross Profit JP¥31.38m Other Expenses JP¥1.94b Earnings -JP¥1.91b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 07, 2025
Earnings per share (EPS) -77.04 Gross Margin 100.00% Net Profit Margin -6,093.40% Debt/Equity Ratio 15.9%
How did 4588 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 08:02 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Oncolys BioPharma Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kiyokazu Yamazaki Ichiyoshi Research Institute Inc.
Show 0 more analysts 
